Takeda Pharmaceutical Co Ltd banner

Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 5 082 JPY 0.97% Market Closed
Market Cap: ¥8.1T

Wall St Price Targets

Price Targets Summary
Takeda Pharmaceutical Co Ltd

Wall Street analysts forecast Takeda Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Takeda Pharmaceutical Co Ltd is 6 375.24 JPY with a low forecast of 5 252 JPY and a high forecast of 8 295 JPY.

Lowest Forecast
Price Target
5 252 JPY
3% Upside
Average Forecast
Price Target
6 375.24 JPY
25% Upside
Highest Forecast
Price Target
8 295 JPY
63% Upside
Takeda Pharmaceutical Co Ltd Competitors:
Price Targets
SITOWS
Sitowise Group Oyj
-7% Downside
MZH
Nanofilm Technologies International Ltd
1% Upside

Revenue
Forecast

9% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
9% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 1%.

Gross Profit
Forecast

8% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
8% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 3 years is 1%.

Operating Income
Forecast

6% / Year
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
-46%
Average Miss
6% / Year
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
-46%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 2 years is -5%.

Pre-Tax Income
Forecast

-3% / Year
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
-3% / Year
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -3%. The projected CAGR for the next 3 years is 34%.

Net Income
Forecast

-1% / Year
Past Growth
43% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-1% / Year
Past Growth
43% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 3 years is 43%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Takeda Pharmaceutical Co Ltd's stock price target?
Price Target
6 375.24 JPY

According to Wall Street analysts, the average 1-year price target for Takeda Pharmaceutical Co Ltd is 6 375.24 JPY with a low forecast of 5 252 JPY and a high forecast of 8 295 JPY.

What is the Revenue forecast for Takeda Pharmaceutical Co Ltd?
Projected CAGR
1%

Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 1%.

What is the Gross Profit forecast for Takeda Pharmaceutical Co Ltd?
Projected CAGR
1%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 3 years is 1%.

What is the Operating Income forecast for Takeda Pharmaceutical Co Ltd?
Projected CAGR
-5%

Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 2 years is -5%.

What is the Pre-Tax Income forecast for Takeda Pharmaceutical Co Ltd?
Projected CAGR
34%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -3%. The projected CAGR for the next 3 years is 34%.

What is the Net Income forecast for Takeda Pharmaceutical Co Ltd?
Projected CAGR
43%

Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 3 years is 43%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett